Also, the IL-13 levels were significantly lower in the control group compared to the AD group (1.25 ± 0.78 vs. 15.55 ± 6.34, p < 0.001) (Figure 2) before treatment with Dupilumab. Here, IL13 is linked to Alzheimer disease.